巖山科技(002195.SZ):海南瑞弘擬參設嘉興瀾晟創業投資合夥企業
格隆匯7月15日丨巖山科技(002195.SZ)公佈,公司全資子公司海南瑞弘創業投資有限責任公司(簡稱“海南瑞弘”)於近日與上海國策投資管理有限公司(簡稱“國策投資”)、上海子璟商務信息管理中心、上海起銘信息科技有限公司共同參與投資嘉興瀾晟創業投資合夥企業(有限合夥)(以下簡稱“基金”或“合夥企業”),並簽署了《嘉興瀾晟創業投資合夥企業(有限合夥)合夥協議》。合夥企業的認繳出資總額爲人民幣4,164萬元,公司全資子公司海南瑞弘作爲有限合夥人認繳出資額爲人民幣2,032萬元,佔認繳出資總額的48.80%。合夥企業將以股權形式最終投向 Bytedance Ltd.。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.